Pyrido(2,3-d) pyrimidine-thiones

ABSTRACT

WHEREIN R is selected from the group consisting of phenyl, substituted phenyl and aralkyl; R1 is selected from the group consisting of hydrogen, lower alkyl, unsaturated lower alkyl, substituted lower alkyl and aralkyl; Y and Z are selected from the group consisting of O and S, but Y and Z are always dissimilar. The compounds of the present invention possess a high degree of pharmacological activities such as anti-inflammatory, anti-ulcerative, analgetic, antipyretic, antihistaminic and central nervous system depressive activities, and certain of them are useful as new anti-inflammatory agents, analgesics and central nervous system depressants. The pyrido(2,3-d)pyrimidinethiones of the present invention can be represented by the following formula:

United States Patent [1 1 Noda et al.

[ 1 Oct. 14, 1975 PYRIDO [2,3-Dl PYRIMIDINE-THIONES [73] Assignee: Hisamitsu Pharmaceutical Co., Inc.,

Tosu, Japan [22] Filed: Oct. 17, 1974 [21] Appl. No.: 515,678

[30] Foreign Application Priority Data Oct. 25, 1973 Japan 48-l2098l [52] U.S. Cl. 260/2565 R; 424/251 [51] Int. Cl? C07D 239/00 [58] Field of Search 260/2565 [56] References Cited UNITED STATES PATENTS 3,272,816 9/1966 Papesch 260/2564 Primary Examiner-Leonard Schenkman Attorney, Agent, or FirmBrowdy and Neimark [57] ABSTRACT The pyrido [2,3-dlpyrimidinethiones of the present invention can be represented by the following formula:

N i l R wherein R is selected from the group consisting of phenyl, substituted phenyl and aralkyl; R is selected from the group consisting of hydrogen, lower alkyl, unsaturated lower alkyl, substituted lower alkyl and aralkyl; Y and Z are selected from the group consisting of O and S, but Y and Z are always dissimilar. The compounds of the present invention possess a high degree of pharmacological activities such as antiinflammatory, anti-ulcerative, analgetic, antipyretic, antihistaminic and central nervous system depressive activities, and certain of them are useful as new antiinflammatory agents, analgesics and central nervous system depressants.

27 Claims, No Drawings PYRIDO(2,3-D) PYRIMIDINE-THIONES DETAILED DESCRIPTION wherein R is selected from the group consisting of phenyl, substituted phenyl with one or two substituents which include halogens, lower alkyl, lower alkoxy and trifluoromethyl groups, benzyl, substituted benzyl with one or two substituents which include halogens, lower alkyl and lower alkoxy groups, and phenethyl; R is selected from the group consisting of hydrogen, lower alkyl, unsaturated lower alkyl, substituted lower alkyl with halogen, hydroxy, lower alkoxy, lower alkanoyloxy, vinyloxy, hydroxy lower alkoxy or lower cycloalkyl, benzyl and phenethyl; Y and Z are selected from the group consisting of O and S, but Y and Z are always dissimilar. The compounds of the present invention possess remarkable pharmacological activities such as anti-inflammatory, anti-ulcerative, analgetic, antipyretic, antihistaminic and central nervous system depressive activities as well as low toxicity, and certain of them are useful as new analgesics, anti-inflammatory agents and central nervous system depressants. All of the compounds of the present invention possess at least one of said pharmacological activities, and most possess more than one of said activities.

More particularly, the present invention relates to the pyrido[2,3-d]pyrimidinethiones represented by the following formula:

wherein R is selected from the .group consisting of phenyl, halophenyl, dihalophenyl, tolyl and trifluoromethylphenyl; R is selected from the group consisting of hydrogen, lower alkyl groups having from 1 to 6 car- 'bon atoms, lower alkenyl groups having from 3 to 5 atoms, vinyloxyethyl, acetoxyethyl, ethoxyethyl and P PARATION 1 Reaction scheme [A] comm cs'x- I T R wherein X is'selected from the group consisting of halogen and imidazolyl; R is selected from the group consisting of phenyl, halophenyl, dihalophenyl and trifluoromethylphenyl; R is selected from the group consisting of lower alkyl, ally], propargyl, cyclopropylmethyl, 2,2,2-trifluoroethyl, 2-acetoxyethyl. and 2- ethoxyethyl. The reactions represented by the reaction scheme [A] are generally carried out in an inert solvent such as tetrahydrofuran, dim e thylformamide, dioxane,

diglyme, benzene, toluene, xylene or alcohol. In the preferred procedure the reaction is carried out in the presence of an alkali metal or metallic compound such as metallic sodium, metallic potassium, sodium hydride, sodium amide or sodium alcoholate, an organic base such as pyridine or trialkylamine, or an inorganic base such as alkali hydroxide or alkali carbonate. The first-mentioned alkali metals and metallic compounds are most effective to enhance the yield of product. The reaction temperature is preferably maintained under cooling with ice when thiophosgene is used as a reactant, and also maintained below the boiling point of the solvent used when 1,1 -thiocarbonyldiimidazole is used. The reaction solvent is distilled off from the reaction mixture under reduced pressure and the residue obtained is mixed, with water to precipitate a crude product. Recrystallization of this product from an organic solverit such as acetone or methanol yields pure crystals.

PREPARATION 2 Reaction scheme [B] O comma N-R RNCS I x! i S N N If (VI) (VII) (II) wherein X is halogen; R. and R have the same meanwherein R is selectedfrom the group. consisting of ing as above. The reactions represented by the reaction phenyl, halophenyl, dihalophenyl, tolyl and trifluoroscheme [B] are preferably carried outin such an ormethylphenyl; R is selected from the group consisting ganic solvent as tetrahydrofuran, diglyme, dichloroof hydrogen, lower'alkyl, ally] and Z-hydroxyethyl.

methane, benzene, toluene, xylene or dimethylform- 5 The reaction representedby the reaction scheme [D],

amide. These reactions should be processed in the presis carried out by heating the pyrido[2,3- ence of a metallic compund such as sodium hyride, sod]pyrimidinedione with phosphorus pentasulfide either dium amide or sodium alcoholate. The reaction temin or without an inert organic solvent. Pyridine, picoperature is not critical, but the reaction proceeds smooline, toluene, xylene or tetralin is utilized as the inert thly near or at the boiling point of the solvent used. The solvent. The reaction is'preferably carried out at the elreaction product can be purified either by recrystallievated temperature ranging from 100C to the boiling zation from an organic solvent such as methanol, ethapoint of the solvent used. The pyrido[2,3- nol, ethyl acetate or acetone, or by column chromatogd]pyrimidinediones of the formula X, the starting maraphy to yield pure crystals. terials used in the reaction scheme [D] in Preparation P I 3 l5 4, can be prepared by the following reaction.

Reactio scheme [C] Reaction scheme [E] Cox 7' CONHR v R NCS -tcoxs,

N NH I NH IL I I I La (VIII) A (IX) (3) (b) I 4x)- I wherein X 15 selected from the groupconsistmg of wherein R and R have the same meamngas above;X

lower alkoxy and amino; R and R have the same and X are the same or different and each represents meaning as above. The reactions represented by the rehalogen,- loweralkoxy, imidazolyl or amino. The examaction scheme [C are generally carried out in an inert ples of the formula (b) include ure"a','methylurea, diethsolvent such as tetrahydrofuran, dimethylformamide, ylurea, N-propylurethane, 1,1-carbonyldiimidazole, dioxane, digylme, benzene, toluene, xylene or alcohol. phosgene; ethyl chlorocarbonate and diethyl carbon- In the preferred procedure these reactions should be ate. I

carried out in the presence of an alkali metal or metallic compound such as metallic sodium, metallic potassium, sodium hydride, sodium amide or sodium alcoho- 40 late to obtain the high yield of the object compound.

PREPARATION 4 COMPOUNDS 7 The object compounds of the present invention can be prepared by the process described in Preparation Reaction scheme [D] I l-4. The examples, of the compounds and the melting o points thereof are shown in Table I.

N-ll

P185 g H4 O L 0 TABLE I N N N N The Examples of the Compounds Obtained by the R Ra Present Invention (X) (III) NN/LY F 3 H H .6 22 2 224 -Continued Compound Melting Point I No. Y z R R (T) 50 .O c1 c 11 23s 236 Br 51 H 248 249 53 -c1-1,c11,c11 180 I82 I 54 O H 230 231 56 c11 c11 c11 189 190 57 c11,c11=cH 173 174 CH s Q 11 237 238 CI 59 Gil-c1 H 298 299 TEST SERIES With respect to'numerous compounds of the present invention, the acute toxicity was tested to ensure their safety, and further central nervous system depressive, anti-inflammatory and analgetic effects were tested to prove their excellent activities. The results of each test are indicated in Table II. Each test was conducted in the following manner.

1. Acute toxicity Each test compound suspended in 0.5 tragacanthsaline solution was administered intraperitoneally or orally to dd-strain male mice (16-24 g). The lethal dose was estimated from the death of animals 72 hours after administration.

2. Anti-inflammatory effect mals. Theinhibition percentages were sown with the notations as follows:

less than 15 l6-30%:+

more than 61 -lH-l- 3. Analgetic Effect 4. Central nervous system depressive effect Each test compound suspended in 0.5 tragacanthsaline solution was injected intraperitoneally to ddstrain male mice (16-24 g). The disappearance of righting reflex was observed under noiseless circumstances. The dose required for the disappearance of righting reflex is indicated with the following notations:

following.

Continued anti-inflaanalgetic C N S acute mmatory" effect deprestoxicity Standard effect ED sive (mg/kg) dose(mg/kg) (95%C.L.) effect 50 l (mg/kg) I i.p.

N-R Y anti-inflaanalgetic C N S acute mmatory effect deprestoxicity effect ED sive' (mg/kg) R dose(mg/kg) (95%C.L.) effect (mg/kg) Y Z R R 50 IO i.p. p.o.

" C H 56.0 1o00 2000 (20.0l5'6.'8) CH CH CH glOO o s -cH -H-+ 100 4+ 300 i000.=200-500 C H l8.0 -HH- 100- 200- F. (7.2644.6) 300 500 u n C2H5 H t -l|l|- CI O CH;, +1+ 28.5 1000 $2000 v ..(6.3635.4) l000 I000 0-0 '-c,H 14-1-1 2100 1000 Br 0 -CH +1-1- 100 |000 -C H 19.5 300 2o00 (837-454) .l000 I I: the 0 cn 100 $1000v (930-755) v (F O l-1 i 100 4 l 5 i c,H 4+ 17.5 300-1 1000- cn,cu,on 15.3 -H+ 1000 1000- (6.7034.9) 2000 Cl .7 0-Cl C=H 4-H- -H-+ 25.0 -H- 300.-" 2000 Examples of the present invention are shown in the EXAMPLE I cooling 3.45 g of thiophosgene which was diluted with a small amount of tetrahydrofuran. The mixture was stirred for minutes at room temperature and then the excess of thiophosgene was decomposed with ammonia-saturated methanol solution under ice-cooling. Then the solvent was distilled off from the reaction mixture to leave the residue, to which was added water 7 d]pyrimidine as colorless needles, melting point at 182183C. Analysis-(galculated for C H BrN OS C:49.74, l-l:3.3j4, NzllfGO. Found C:49.78, l-lz3.3l,

' EXAMPLE 2 To a solutidn of g of 2-(m-trifluoromethylanilino)nicotinethylamide in 50 ml of tetrahydroand the whole was stirred for 1 hour at room tempe ra ture and then refluxed for hours. After the reaction was finished, the solvent was evaporated from the mixture to leave the residue, to which was added water to precipitate a crude product. Recrystallization of this product from methanol gave 2.4 g of l-(mtrifluoromethylphenyl)-3-ethyl-2-thio-4-oxo-1,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidine as colorless prisms, melting at 158159C. Analysis-Calculated for C H F N OS C:54.70, 1113.44, N21 1.96. Found C:54.69, H:3.48, N:12.01.

EXAMPLE 3 To a mixture of 1.8 g of 2-chloronicotinethylamide and ml of dry dimethlformamide was added 1.0 g of 50 sodium hydride and stirring was continued for 30 minutes at room temperature. To this was further added 1.6 g of phenylisothiocyanate and the mixture was refluxed for 3 hours, and then the solvent was distilled off under reduced pressure. The residue thus obtained was dissolved in a small amount of chloroform and the chloroform solution was chromatographed on a column of silica gel and the product was then eluted with chloroform. The eluate was evaporated to dryness and the combined product was recrystallized from methanol to yield 2.0 g of 1-phenyl-3-ethyl-2-thio-4- oxo-l ,2,3,4-tetrahydropyrido[ 2,3-d]pyrimidine as pale yellow prisms, melting at 211212C. Analysis- Calculated for C I-1 N 08 C:63.58, H:4.62, N:l4.83. Found 1 C:63.63, H:4.57, N:14.77.

EXAMPLE 4 To a solution of 2.0 g of 2- chloronicotinisopropylamide and 20 ml of dry dimethylformamide was added 1.0 g of 50 sodium hydride and the mixture was stirred for 30 minutes at room temperature. To this was further added 2.8 g of m-bromophenylisothiocyanate and the mixture was refluxed for 4 hours. The solvent was distilled off from the reaction mixture under reduced pressure. The residue thus obtained was chromatographed on a silica gel column and the product was eluted with chloroform. The eluate was evaporated to dryness and the combined product was recrystallized from acetone to give 2.6 g of 1-(m-bromophenyl)-3-isopropyl-2-thio-4-oxo- 1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine as colorless prisms, melting at 190191C. Analysis-Calculated for C H BrN os C:51.07, H:3.75, N:11.17. Found C:5l.l2, H:3.71, N:11.09.

EXAMPLE 5 To a solution of 2.8 g of 2-(m-chloroanilino)nicotinic acid ethyl ester and ml of dry tetrahydrofuran was added 0.6 g of sodium hydride and the mixture was stirred for minutes. To this was further added 1.1 g of ethylisothiocyanate and the mixture was refluxed for 3 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and the residue was chromatographed on a column of silica gel. The product was eluted with chloroform and the eluate was evaporated to dryness. The combined product was recrystallized from methanol to give 1.9 g of l-(mchlorophenyl )-3-ethyl-2-thio-4-oxo-1 ,2,3,4-tetrahydropyrido[2,3-d]pyrimidine as colorless prisms, melting at 214215C. Analysis-Calculated for C H ClN OS C:56.69, H:3.8l, N:13.22. Found C:56.65, H:3.83, N:13.18.

EXAMPLE 6 To a solution of 3.1 g of Z-(m-trifluoromethylanilino)nicotinic acid ethyl ester and 25 ml of dry tetrahydrofuran was added 0.47 g of sodium amide and stirring of the mixture was continued for 1 hour at room temperature. To this was further added 0.9 g of methylisothiocyanate and the mixture was refluxed for 5 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and the residue was chromatographed on a column of silica gel. The product was eluted with chloroform and the eluate was evaporated to dryness. The combined product was recrystallized from methanol to yield 2.1 g of l-(mtrifluoromethylphenyl )3-methyl-2-thio-4-oxo-l ,2,3,4- tetrahydropyrido[2,3-d]pyrimidine as pale yellow prisms, melting at 198-200C. Analysis-Calculated for C H F N OS C:53.41, l H2299, N:12.46. Found C:53.38, H:3.04, N:12.41.

EXAMPLE 7 A mixture of 1.54 g of 1-(3,4-dichlorophenyl)-2,4- dioxo-l,2,3,4-tetrahydropyrido[2,3-d1pyrimidine, 1.7 g of phosphorus pentasulfide and 20 ml of pyridine was refluxed for 8 hours. After the reaction was over, pyridine was distilled off from the mixture under reduced pressure and to the residue was added water. This solution was allowed to stand overnight at room temperature to yield the precipitate which was then separated by filtration. Recrystallization of this product from acetone gave 1.47 g of l-(3,4-dichl0r0phenyl)-2-ox0-4- thio-l,2,3,4-tetrahydropyrido[2,3-d]pyrimidine as pale yellow needles, melting at 298299C. Analysis- Calculated for C H Cl N OS C:48.l6, H:2.l9, N:12.96. Found: C:48.21, H:2.02, N:12.82.

EXAMPLE 8 A mixture of 1.43 g of l-(m-fluorophenyl)-3-ethyl- 2,4-dioxo-1 ,2,3 ,4-tetrahydropyrido[2,3-d1pyrimidine, 1.7 g of phosphorus pentasulfide and 30 ml of xylene was refluxed for 3 hours. Xylene was distilled off from the mixture under reduced pressure to leave the residue, to which was added water. The solution was extracted with three 30 ml portions of chloroform. The chloroform layer was washed with water, dehydrated and evaporated to remove the solvent. The residual solid obtained was recrystallized with ether to yield 1.23 g of 1(m-fluorophenyl)-3-ethyl-2-oxo-4-thio- 1,2,3,4-tetrahydropyrid0[2,3-d]pyrimidine as yellow needles, melting at 156C. Analysis-Calculated for C l-1 FN OS C:59.78, 1114.01, N:13.94. Found C:59.62, H:3.98, N:l3.82.

EXAMPLE 9 A mixture of 1.8 g of 1-(m-bromophenyl)-3-propyl- 2,4-dioxol ,2,3,4-tetrahydropyrido[2,3-d]pyrimidine, 1.7 g of phosphorus pentasulfide and 30 ml of xylene was refluxed for 2 hours. Xylene was evaporated under reduced pressure from the mixture to leave the residue, to which was added water. The solution was extracted with three 30 ml portions of chloroform. The chloroform layer was washed with water, dehydrated and evaporated under reduced pressure to remove the solvent. The residual solid was recrystallized from acetone to give 1.68 g of 1-(m-bromophenyl)-3-propyl-2-oxo-4- thio- 1 ,2,3 ,4-tetrahydropyprido[ 2,3-d1pyrimidine as pale yellow needles, melting at 180-182C. Analysis- Calculated for C H BrN OS C:51.07, H:3.75, N:1l.l6. Found C:5l.12, H:3.82, N:l 1.18.

What is claimed is:

1'. A compound of the formula wherein R is selected from the group consisting of phenyl, halophenyl, dihalophenyl, tolyl and trifluoromethylphenyl R is selected from the group consisting of hydrogen, lower alkyl having from 1 to 6 carbon atoms, lower alkenyl having from 3 to 5 carbon atoms, propargyl, cyclopropylmethyl, trihaloalky] having from 1 to 3 carbon atoms, vinyloxyethyl, acetoxyethyl, ethoxyethyl and lower hydroxyalkyl having from 2 to 3 carbon atoms Y and Z are selected from the group consisting of O and S, but Y and Z are always dissimilar.

2. A compound in accordance with claim 1 of the formula:

wherein R is selected from the group consisting of phenyl, halophenyl, dihalophenyl and trifluoromethylphenyl R is selected from the group consisting of lower alkyl having from one to 6 carbon atoms, allyl, propargyl, cyclopropylmethyl, 2,2,2-trifluoroethyl, 2- acetoxyethyl and 2-ethoxyethyl.

3. A compound in accordance with claim 1 of the formula:

wherein R is selected from the group consisting of phenyl, halophenyl, dihalophenyl, tolyl and trifluoromethylphenyl R" is selected from the group consisting of hydrogen, lower alkyl having from one to 6 carbon atoms, allyl and 2-hydroxyethyl.

4. A compound in accordance with claim 1 which is: 1-phenyl-3-ethyl-2-thio-4-oxol ,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidine. 5. A compound in accordance with claim 1 which is: 1-( m-fluorophenyl )-3-methy1-2-thio-4-oxol ,2,3 ,4,-

tetrahydropyrido[2,3-d]pyrimidine. 6. A compound in accordance with claim 1 which is: l-(m-fluorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3 ,4-tetrahydropyrido[2,3-d]pyrimidine. 7. A compound in accordance with claim 1 which is:

l-(p-fluorophenyl)-3-methyl-2-thio-4-oxo-1,2,3,4-

tetrahydropyrido[2,3-d]pyrimidine.

8. A compound in accordance with claim 1 which is:

1-(p-fluorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine.

9. A compound in accordance with claim 1 which is:

1-( m-chlorophenyl )-3-methyl-2-thio-4-oxol ,2,3 ,4-

tetrahydropyrido[2,3-d]pyrimidine.

10. A compound in accordance with claim 1 which 1-(m-chlorophenyl)-3-ethyl-2-thio-4-oxo-l ,2,3,4-tetrahydropyrido[2,3-d]pyrimidine.

11. A compound in accordance with claim 1 which is:

1-( m-bromophenyl )-3-ethyl-2-thio-4-oxo-l ,2,3 ,4-

tetrahydropyrido[2, 3-d]pyrimidine.

12. A compound in accordance with claim 1 which is:

l-(m-iodophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido[ 2,3 -d lpyrimidine.

13. A compound in accordance with claim 1 which is:

1-( m-trifluoromethylphenyl )-3-ethyl-2-thio-4-oxo- 1,2,3 ,4-tetrahydropyrido[ 2,3-dIpyrimidine.

14. A compound in accordance with claim 1 which is:

1-( 3 ,4-dichlorophenyl )-3-ethyl-2-thio-4-oxo- 1 ,2,3 ,4,-tetrahydropyrido[2,3-d]pyrimidine.

. 15. A compound in accordance with claim 1 which 1-phenyl-3-methyl-2-oxo-4-thio-l ,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidine.

16. A compound in accordance with claim 1 which 1 -pheny1-3-ethyl-2-oxo-4 thio-1 ,2,3 ,4-

tetrahydropyridol2,3-d]pyrimidine.

17. A compound in accordance with claim 1 which is:

rahydropyrido[2,3-d]pyrimidine.

18. A compound in accordance with claim 1 which is:

l-(m-chlorophenyl )-3-methyl-2-Oxo-4-thio-1 ,2,3,4-

tetrahydropyrido[2,3-d]pyrimidine.

19. A compound in accordance with claim 1 which is:

1-( m-chlorophenyl)-3-ethyl-2-oxo-4-thio-1 ,2,3 ,4-tetrahydropyrido[2,3-d]pyrimidine.

20. A compound in accordance with claim 1 which is:

1 -(p-chlorophenyl )-3-ethyl-2-oxo-4-thiol ,2,3,4tetrahydropyrido[ 2,3 -d pyrimidine.

21. A compound in accordance with claim 1 which is:

1-(m-bromophenyl)-3-methyl-2-oxo-4-thiol ,2,3 ,4-

tetrahydropyrido[2,3-d]pyrimidine.

22. A compound in accordance with claim 1 which is:

l-(m-bromphenyl)-3-ethyl-2-oxo-4-thio-1 ,2,3,4-tetrahydropyrido[2,3-d]pyrimidine.

23. A compound in accordance with claim 1 which is:

l-(m-iodophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine.

24. A compound in accordance with claim 1 which is:

l-(m-trifluoromethylphenyl)-3-(2-hydroxyethyl)-2- 5 is:

oxo-4-thio-l ,2,3 ,4-tetrahydropyrido[2,3- dlpyrimidine. 26. A compound in accordance with claim 1 which l(3,4-dichlorophenyl)-3-ethyl-2-oxo-4-thio-l,2,3,4-

tetrahydropyrido[2,3-d1pyrimidine. 27. A compound in accordance with claim 1 which l-( 3,4-dichlorophenyl)-3-ethyl-2-oxo-4-thiol ,2,3,4;-tetrahydropyrido[2,3-d1pyrimidine.

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION PATENT N01 3,912,736 DATED October 14, 1975 |NVENTOR(S) Kanji NODA et al It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

The formula appearing in the Abstract, in Column 1, lines 10 and 50, Column 4 (Table I), and Columns 9, l0 and 11, should read as follows:

The formula in Column 2, line 15, should read as follows O 2 CONHR H 2 1 CSX2 /\N"R \NH 1 (IV) (V) (II) Signed and Sealed this sixteenth Day of March 1976 [SEAL] Attest:

RUTH C. MASON Arresting Officer C. MARSHALL DANN Commissioner nj'Patems and Trademarks 

1. A COMPOUND OF THE FORMULA
 2. A compound in accordance with claim 1 of the formula:
 3. A compound in accordance with claim 1 of the formula:
 4. A compound in accordance with claim 1 which is: 1-phenyl-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3-d)pyrimidine.
 5. A compound in accordance with claim 1 which is: 1-(m-fluorophenyl)-3-methyl-2-thio-4-oxo-1,2,3,4,-tetrahydropyrido( 2,3-d)pyrimidine.
 6. A compound in accordance with claim 1 which is: 1-(m-fluorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 7. A compound in accordance with claim 1 which is: 1-(p-fluorophenyl)-3-methyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 8. A compound in accordance with claim 1 which is: 1-(p-fluorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 9. A compound in accordance with claim 1 which is: 1-(m-chlorophenyl)-3-methyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 10. A compound in accordance with claim 1 which is: 1-(m-chlorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 11. A compound in accordance with claim 1 which is: 1-(m-bromophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 12. A compound in accordance with claim 1 which is: 1-(m-iodophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 13. A compound in accordance with claim 1 which is: 1-(m-trifluoromethylphenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4 -tetrahydropyrido(2,3-d)pyrimidine.
 14. A compound in accordance with claim 1 which is: 1-(3,4-dichlorophenyl)-3-ethyl-2-thio-4-oxo-1,2,3,4,-tetrahydropyrido(2,3 -d)pyrimidine.
 15. A compound in accordance with claim 1 which is: 1-phenyl-3-methyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3-d)pyrimidine.
 16. A compound in accordance with claim 1 which is: 1-phenyl-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3-d)pyrimidine.
 17. A compound in accordance with claim 1 which is: 1-(m-fluorophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 18. A compound in accordance with claim 1 which is: 1-(m-chlorophenyl)-3-methyl-2-Oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 19. A compound in accordance with claim 1 which is: 1-(m-chlorophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 20. A compound in accordance with claim 1 which is: 1-(p-chlorophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 21. A compound in accordance with claim 1 which is: 1-(m-bromophenyl)-3-methyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 22. A compound in accordance with claim 1 which is: 1-(m-bromphenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 23. A compound in accordance with claim 1 which is: 1-(m-iodophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 24. A compound in accordance with claim 1 which is: 1-(m-trifluoromethylphenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4 -tetrahydropyrido(2,3-d)pyrimidine.
 25. A compound in accordance with claim 1 which is: 1-(m-trifluoromethylphenyl)-3-(2-hydroxyethyl)-2-oxo-4-thio-1,2, 3,4-tetrahydropyrido(2,3-d)pyrimidine.
 26. A compound in accordance with claim 1 which is: 1-(3,4-dichlorophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4-tetrahydropyrido(2,3 -d)pyrimidine.
 27. A compound in accordance with claim 1 which is: 1-(3,4-dichlorophenyl)-3-ethyl-2-oxo-4-thio-1,2,3,4,-tetrahydropyrido(2,3 -d)pyrimidine. 